Skip to main content
. 2020 Feb 4;11(5):523–534. doi: 10.18632/oncotarget.27458

Table 1. Expression and methylation of SMPD3 in patient-matched dysplasia and CIS/OSCC samples.

Dysplasia CIS/OSCC
Hypermethylateda 6 10
Downregulatedb 5 6
Hypermethylated and downregulated in the same patient 4 6

aΔβ-value of ≥0.15 compared with adjacent normal tissue in at least one CpG within the SMPD3 promoter. bFold-change of ≥2 compared with adjacent normal tissue in at least one SMPD3 probe. N = 10.